BLENREP▼ (Belantamab mafodotin) logo

Product menu

BLENREP ▼ (belantamab mafodotin) is indicated in adults for the treatment of multiple myeloma:4

  • In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
  • In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide
Explore the current challenges in multiple myeloma at first relapse

Explore the challenge of treating relapsed or refractory multiple myeloma

Discover the need for improved outcomes in lenalidomide-refractory patients

Learn more about switching MoA at first relapse

Help your eligible adult patients navigate first relapse with BLENREP ▼ (belantamab mafodotin)

Image showing a dose delay icon

The challenge of treating relapsed or refractory multiple myeloma

Patients with relapsed or refractory multiple myeloma are heterogenous and need new options at second line (2L) to improve outcomes and tailor therapy to patients needs.4 Many patients value treatments that offer prolonged remission and improved survival, and are willing to tolerate some side effects for higher efficacy, while also valuing ease of administration.5

Image showing a clipboard icon

Improving outcomes in 2L in multiple myeloma – providing lasting remission

The prognosis and choice of treatment for patients with relapsed and refractory multiple myeloma are influenced by factors such as prior treatments, disease biology, patient comorbidities, renal impairment, and advanced age or frailty.6

Current treatment options for relapsed and refractory multiple myeloma have led to improvements in life expectancy, with a 5-year survival rate of approximately 55%.7 However, despite survival improvements, only 10–15% achieve or exceed expected survival outcomes compared with the general population.8

Using the most effective treatment option in 2L

As patients relapse, treatment resistance becomes a significant hurdle.3 Patients with multiple myeloma often weigh the benefits of treatment against the burden of side effects and the impact on their quality of life, highlighting the importance of treatment options that are both effective and tolerable.9

Figure showing UK patients receiving active treatment

Adapted from Raab et al. 2019.

View full figure

Therefore, patients need the most effective option available at each line of therapy, as their choices become increasingly limited.11

Treatments with differentiated mechanisms of action, such as BLENREP, offer new options to eligible adult patients at first relapse.12,13

The need for improved outcomes in lenalidomide-refractory patients

The extensive use of lenalidomide (LEN)-based therapy in the first line (1L) has led to a growing proportion of patients becoming LEN-refractory at first relapse.15

These patients face worse outcomes at each treatment line, with notably shorter mPFS compared with the intent-to-treat (ITT) population (DVd;16.7 vs 7.8 months, Kd; 18.7 vs 8.6 months, SVd; 13.9 vs 10.2 months).7,16–20

This highlights the ongoing need to identify and optimise treatment strategies that can deliver improved efficacy for the LEN-refractory population.

Post hoc analyses indicate that LEN-refractory patients need additional treatment options at first relapse

Current LEN-sparing regimens and mPFS efficacy in the lenalidomide-refractory subgroup.15–19

  Median progression-free survival
LEN-sparing regimen Trial ITT LEN-refractory subgroup
DVd15 CASTOR 16.7 months 7.8 months
Kd16,17 ENDEAVOR 18.7 months 8.6 months
SVd18,19 BOSTON 13.9 months 10.2 months

Studies were not conducted on a head-to-head basis. Table intended to illustrate differences between ITT and LEN-refractory subgroup populations; not for direct comparison of studies.

Based on clinical trial data, the median progression-free survival (mPFS) of LEN-refractory patients is under or around 10 months.15–19

Switching mechanism of action at first relapse

At first relapse, there are many factors to consider when choosing 2L treatment, including:20

  • Regimen used at 1L and if maintenance was used
  • Quality and duration of first response achieved
  • Side effects from 1L therapy
  • Patient lifestyle factors, including whether potential side effects may impact day-to-day driving ability or occupational responsibilities
  • Patient-related factors such as functional age and performance status
Ticked checkbox

Using therapies with a different MoA may help to overcome drug resistance in multiple myeloma, improving patient outcomes.21,22

Help your eligible adult patients navigate first relapse with BLENREP ▼ (belantamab mafodotin)

The first approved B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) treatment for use in multiple myeloma.4,23–26

BLENREP + Vd (bortezomib and dexamethasone) demonstrates superiority vs DVd (daratumumab, bortezomib, and dexamethasone) with an mPFS of 36.6 months vs 13.4 months, offering patients a chance of a longer life.*†4,27

In DREAMM-7, the most frequently reported non-eye related side effects (≥20%) were thrombocytopenia (87%), diarrhoea (32%), and upper respiratory tract infections (URTIs) (20%).4

The most frequently reported eye-related side effects in DREAMM-7 (≥20%) were reduced visual acuity (89%), corneal examination findings (86%), blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%) and eye pain (32%).4

Explore the DREAMM-7 trial overview

BLENREP + Pd (pomalidomide and dexamethasone) delays disease progression with the mPFS not reached at 22.4 months of follow-up vs 12.7 months with PVd (pomalidomide, bortezomib, and dexamethasone).‡4

In DREAMM-8, the most frequently reported non-eye-related side effects (≥20%) were neutropenia (63%), thrombocytopenia (55%), fatigue (27%), URTIs (27%), pneumonia (24%), anaemia (23%), and diarrhoea (23%).4

The most frequently reported eye-related side effects (≥20%) in DREAMM-8 included reduced visual acuity (91%), corneal examination findings (87%), blurred vision (79%), neutropenia (63%), foreign body sensation in eyes (61%), dry eye (61%), eye irritation (50%), photophobia (44%) and eye pain (33%).4

Explore the DREAMM-8 trial overview

*mPFS was 36.6 months (95% confidence interval [CI]: 28.4–not reached [NR]) in the BVd group and 13.4 months (95% CI: 11.1–17.5) in the DVd group. Hazard ratio (HR) for disease progression or death, 0.41; 95% CI: 0.31–0.53; P<0.00001). †36-month survival in BVd was 74% (N=243) (95% CI: 68–79) vs 60% (N=251) in DVd (95% CI: 54–66) (HR 0.58; 95% CI: 0.43–0.79; p=0.00023). Median overall survival (OS) in either arm was not reached. Median follow-up of 39.4 months. ‡Data cut-off January 2024; probability of PFS at 12 months for BPd was 71% (95% CI 63–78); and for PVd 51% (95% 42–60). HR: 0.52 (95% CI 0.37–0.73).

Abbreviations

1L, first line; 2L, second line; 3L, third line; 4L, fourth line; 5L, fifth line; ADC, antibody-drug conjugate; BCMA, B-cell maturation antigen; CI, confidence interval; DVd, daratumumab, bortezomib and dexamethasone; HR, hazard ratio; ITT, intention-to-treat; Kd, carfilozomib, dexamethasone; LEN, lenalidomide; MOA, mechanism of action; mPFS, median progression-free survival; NR, not reached; OS, overall survival; PVd, pomalidomide, bortezomib, and dexamethasone; SVd, selinexor, bortezomib and dexamethasone; Vd, bortezomib and dexamethasone.

References

  1. Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016 Oct;175(2):252–64.
  2. Kocaata Z, Wilke T, Fischer F, Welte R, Einsele H. Healthcare resource utilization and cost of patients with multiple myeloma in Germany: A retrospective claims data analysis. Pharmacoeconom Open. 2022 Jul;6(4):619–28.
  3. Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Rev. 2021 Sep;49(100808):100808.
  4. BLENREP. Summary of Product Characteristics. GlaxoSmithKline; 2025.
  5. Thomas C, Ailawadhi S, Popat R, Kleinman D, Ross MM, Gorsh B, et al. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment. Front Med (Lausanne). 2023 Nov 23;10:1271657.
  6. Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A. Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results. EJHaem. 2023 Nov 2;4(4):1117–31.
  7. Bhatt P, Kloock C, Comenzo R. Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023 Feb 15;30(2):2322–47.
  8. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Mar 1;32(3):309–22.
  9. Dombeck C, Swezey T, Gonzalez Sepulveda JM, Reeve BB, LeBlanc TW, Chandler D, et al. Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study. BMC Cancer. 2023 Jan 19;23(1):65.
  10. Raab MS, Fink L, Schoen P, Gonzalez-McQuire S, Flinois A, Cavo M, et al. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. Br J Haematol. 2019 Jun 1;185(5):981–4.
  11. Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J 2022;12:98.
  12. Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024 Aug 1;391(5):393–407.
  13. Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024 Aug 1;391(5):408–21.
  14. Moore S, Cornic L, Crossman-Barnes CJ, Jose S, Khalaf Z, Yong K, et al. Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England. EJHaem. 2025 Feb;6(1):e1058.
  15. Mateos MV, Sonnevold P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: Three-year follow-up of CASTOR. Clinical Lymphoma,Myeloma & Leukemia 2019;20:509-518.
  16. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol, 2016;17:27-38.
  17. Moreau P, Joshua D, Chng W-J, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia 2017;31:115–122.
  18. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396:1563–1573.
  19. Mateos MV, Engelhardt M, Leleu M, et al. Efficacy, survival and safety of selinexor, bortezomib and dexamethasone (SVd) in patients with lenalidomide-refractory multiple myeloma: Subgroup data from the BOSTON trial. Presented at EHA Hybrid Congress 2023. June 8-11, 2023. Poster #P886.
  20. Devarakonda S, Sharma N, Efebera Y. The first relapse in multiple myeloma: how to pick the next best thing. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):560–8.
  21. Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev 2018;70:199-208.
  22. Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma - a promising key to therapy. J Clin Med 2021;10(18):4088.
  23. Darzalex. Summary of Product Characteristics. Janssen-Cilag Ltd.
  24. Kyprolis. Summary of Product Characteristics. Amgen Ltd.
  25. Nexpovio. Summary of Product Characteristics. Menari Stemline UK Ltd.
  26. Revlimid. Summary of Product Characteristics. Bristol Myers Squib Pharma limited.
  27. Hungria V, Robak P, Hus M, et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of the Phase 3 DREAMM-7 Trial. Presented at: 66th American Society of Hematology (ASH) Annual Meeting & Exposition; December 7-10, 2024; San Diego, CA, and virtual.

▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.

October 2025 | PM-GB-BLM-WCNT-250014 (V1.0)